Kura Oncology (KURA) Share-based Compensation (2014 - 2026)

Kura Oncology (KURA) has 13 years of Share-based Compensation data on file, last reported at $8.4 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $8.4 million, up 7.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $37.7 million (up 13.41% YoY), and the FY2025 annual result was $37.1 million, up 9.47% from the prior year.
• Share-based Compensation retreated to $8.4 million in Q1 2026 per KURA's latest filing, from $11.4 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $11.4 million in Q4 2025 and troughed at $6.4 million in Q3 2022.
• A 5-year average of $7.9 million and a median of $7.2 million in 2023 frame the typical range for Share-based Compensation.
• On a YoY basis, Share-based Compensation climbed as much as 31.73% in 2025 and fell as far as 17.57% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $6.8 million in 2022, then gained by 5.32% to $7.2 million in 2023, then gained by 20.43% to $8.6 million in 2024, then surged by 31.53% to $11.4 million in 2025, then retreated by 25.86% to $8.4 million in 2026.
• Business Quant data shows KURA's Share-based Compensation at $8.4 million in Q1 2026, $11.4 million in Q4 2025, and $11.0 million in Q3 2025.